BRPI0807604A2 - Composto, composição farmacêutica, e, métodos para tratar, prevenir ou controlar deprressão, dor, ansiedade, e incontiência - Google Patents

Composto, composição farmacêutica, e, métodos para tratar, prevenir ou controlar deprressão, dor, ansiedade, e incontiência Download PDF

Info

Publication number
BRPI0807604A2
BRPI0807604A2 BRPI0807604-9A BRPI0807604A BRPI0807604A2 BR PI0807604 A2 BRPI0807604 A2 BR PI0807604A2 BR PI0807604 A BRPI0807604 A BR PI0807604A BR PI0807604 A2 BRPI0807604 A2 BR PI0807604A2
Authority
BR
Brazil
Prior art keywords
desmethylvenlafaxine
hydrochloride salt
compound
crystalline form
crystalline
Prior art date
Application number
BRPI0807604-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Sizensky
Harold S Wilkinson
John Snoorian
Norman Kim
Sharon M Aughlin
Roger P Bakale
Kevin Plunkett
Pstrick Mousou
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of BRPI0807604A2 publication Critical patent/BRPI0807604A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
BRPI0807604-9A 2007-02-21 2008-02-21 Composto, composição farmacêutica, e, métodos para tratar, prevenir ou controlar deprressão, dor, ansiedade, e incontiência BRPI0807604A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90295007P 2007-02-21 2007-02-21
US60/902950 2007-02-21
PCT/US2008/002379 WO2008103461A2 (en) 2007-02-21 2008-02-21 Solid forms comprising (-) o-desmethylvenlafaxine and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0807604A2 true BRPI0807604A2 (pt) 2014-07-22

Family

ID=39432564

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807604-9A BRPI0807604A2 (pt) 2007-02-21 2008-02-21 Composto, composição farmacêutica, e, métodos para tratar, prevenir ou controlar deprressão, dor, ansiedade, e incontiência

Country Status (18)

Country Link
US (2) US20090005457A1 (enExample)
EP (2) EP2114863B1 (enExample)
JP (1) JP5666140B2 (enExample)
KR (1) KR101528326B1 (enExample)
CN (1) CN101663263A (enExample)
AR (1) AR065431A1 (enExample)
AU (1) AU2008218997B2 (enExample)
BR (1) BRPI0807604A2 (enExample)
CA (1) CA2678599C (enExample)
ES (1) ES2609264T3 (enExample)
IL (1) IL200514A (enExample)
MX (1) MX2009008705A (enExample)
NZ (2) NZ579137A (enExample)
RU (1) RU2477269C2 (enExample)
SG (1) SG175611A1 (enExample)
TW (1) TWI446903B (enExample)
WO (1) WO2008103461A2 (enExample)
ZA (1) ZA200905698B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100015923A (ko) * 2007-04-09 2010-02-12 세프라코 아이엔시. 수면관련 호흡 장애를 치료하는 방법들 및 수면관련 호흡 장애 치료용 조성물들
CZ2008756A3 (cs) * 2008-11-27 2010-03-24 Zentiva, A. S. Zpusob prípravy desvenlafaxinu a jeho solí
CZ302145B6 (cs) * 2009-07-15 2010-11-10 Zentiva, K. S. Zpusob prípravy desvenlafaxinu a jeho solí
CN102249936B (zh) * 2010-05-19 2014-09-17 江苏豪森医药集团有限公司 O-去甲基文拉法辛盐酸盐的水合物及其制备方法
CA2773948A1 (en) * 2011-04-12 2012-10-12 Geo. Pfau's Sons Company, Inc. Method for rendering animal materials
CN103772220A (zh) * 2013-12-03 2014-05-07 镇江圣安医药有限公司 1-[2-二甲基氨基-1-（4-甲氧基苯基）乙基]环己醇的新型衍生物及其应用
CN105348119B (zh) * 2015-11-04 2017-09-15 江苏豪森药业集团有限公司 晶状的文拉法辛代谢物及其制备方法
WO2018146529A1 (en) * 2017-02-09 2018-08-16 R L Finechem Private Limited A process for preparation of1-[2-(dimethylamino)-1-(4-hydroxyphenyl) ethyl]-cyclohexanol and salts thereof
CN109771380A (zh) * 2017-11-10 2019-05-21 连云港恒运药业有限公司 去甲文拉法辛盐酸盐药物组合物及其制备方法
JP7315256B2 (ja) 2018-12-05 2023-07-26 ヘッジホッグ，インコーポレイテッド エンドセリン受容体ａ活性調節抗体
WO2021243351A2 (en) * 2020-05-26 2021-12-02 Mars, Incorporated Process for preparing pet food and pet food obtainable thereby
CN116199590B (zh) * 2022-12-26 2024-12-24 湖北美林药业有限公司 一种盐酸多巴酚丁胺及其注射剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5213738A (en) 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
AU5738700A (en) * 1999-06-15 2001-01-02 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
BR0207157A (pt) * 2001-02-12 2004-02-17 Wyeth Corp Sal de succinato de o-desmetil-venlafaxina
IL162255A0 (en) * 2001-12-05 2005-11-20 Wyeth Corp Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
NZ537142A (en) 2002-06-10 2008-01-31 Wyeth Corp Novel formate salt of O-desmethyl-venlafaxine
JP2009500420A (ja) * 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びｏ−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法

Also Published As

Publication number Publication date
KR20090113904A (ko) 2009-11-02
TW200901955A (en) 2009-01-16
JP2010519300A (ja) 2010-06-03
KR101528326B1 (ko) 2015-06-11
IL200514A (en) 2013-12-31
RU2477269C2 (ru) 2013-03-10
NZ579137A (en) 2012-05-25
EP2500337A3 (en) 2012-12-26
SG175611A1 (en) 2011-11-28
RU2009135016A (ru) 2011-03-27
US20160355457A1 (en) 2016-12-08
CA2678599A1 (en) 2008-08-28
US20090005457A1 (en) 2009-01-01
EP2500337A2 (en) 2012-09-19
MX2009008705A (es) 2009-09-10
AR065431A1 (es) 2009-06-10
CN101663263A (zh) 2010-03-03
ZA200905698B (en) 2010-10-27
AU2008218997A1 (en) 2008-08-28
WO2008103461A2 (en) 2008-08-28
TWI446903B (zh) 2014-08-01
JP5666140B2 (ja) 2015-02-12
CA2678599C (en) 2015-11-10
EP2114863A2 (en) 2009-11-11
ES2609264T3 (es) 2017-04-19
IL200514A0 (en) 2010-04-29
AU2008218997B2 (en) 2013-06-20
EP2114863B1 (en) 2016-10-05
WO2008103461A3 (en) 2008-11-13
NZ599480A (en) 2013-10-25

Similar Documents

Publication Publication Date Title
BRPI0807604A2 (pt) Composto, composição farmacêutica, e, métodos para tratar, prevenir ou controlar deprressão, dor, ansiedade, e incontiência
US6197828B1 (en) Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6342533B1 (en) Derivatives of (−)-venlafaxine and methods of preparing and using the same
CN107750245A (zh) S‑氯胺酮的(s)‑csa盐、s‑氯胺酮的(r)‑csa盐和用于制备s‑氯胺酮的方法
EP1466889A1 (en) Derivatives of venlafaxine and methods of preparing and using the same
BR112020011189A2 (pt) misturas não racêmicas e usos das mesmas
JP5766713B2 (ja) トランスノルセルトラリンの製剤、塩、及び多形体、並びにその使用
JP6610793B2 (ja) 環状アミン誘導体の結晶及びその医薬用途
BRPI0613031A2 (pt) composto, composiÇço farmacÊutica; uso do composto para a manufatura de um medicamento para tratar sÍndrome do intestino irritÁvel, tratar dor ou sÍndromes dolorosas, tratar incontinÊncia urinÁria, tratar depressço, fibromialgia, ansiedade, distérbio do pÂnico, agorofobia, distérbio de estresse pàs-traumÁtico, distérbio disfàrico prÉ-menstrual, distérbio do dÉficit de atenÇço, distérbio obsessivo compulsivo, distérbio de ansiedade social, distérbio de ansiedade generalizado, autismo, esquizofrenia, obesidade, anorexia nervosa, bulimia nervosa, sÍndrome de gilles de la tourette, descarga vasomotora, vÍcio de cocaÍna e Álcool, disfunÇço sexual, distérbio de limiar de personalidade, sindrome de fibromialgia, dor neuropatica diabÉtica, sÍndrome de fadiga crânica, sÍndrome de shy drager, sÍndrome de raynaud, doenÇa de parkinson, e epilepsia, mÉtodo de preparar um composto da estrutura (a), e mÉtodo de preparar um composto da estrutura (b)
HK1141271A (en) Solid forms comprising (-) o-desmethylvenlafaxine and uses thereof
BR122014004640B1 (pt) Forma cristalina iii de [cloridrato de 4-metilbenzoato de 4-[2-dimetilamino-1-(1-hidroxiciclohexil)etil]fenila], sua utilização e seu método de preparação, e composição farmacêutica
TWI490189B (zh) Ｏ－去甲基文拉法辛鹽酸鹽的水合物及其製備方法
HK1251546B (zh) S-氯胺酮的(s)-csa盐、s-氯胺酮的(r)-csa盐和用於制备s-氯胺酮的方法
AU3106200A (en) Derivatives of (+)-venlafaxine and methods of preparing and using the same

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements